Brevan Howard Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

Brevan Howard Capital Management’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$231K	Buy	+21,474	New	+$175K	﹤0.01%	1844

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCA

Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Brevan Howard Capital Management's FENC Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Fennec Pharmaceuticals (FENC) in Q2 2026: 21,474 shares worth $231K. The stake represents ﹤0.01% of the portfolio and ranks #1844 among its holdings.

104 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

Brevan Howard Capital Management held 21,474 shares of Fennec Pharmaceuticals worth $231K as of Q2 2026.
Fennec Pharmaceuticals was a new Brevan Howard Capital Management position in Q2 2026.
Fennec Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1844 holding.
104 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.